In 997 infants at increased risk of severe RSV disease, one dose of clesrovimab 105 mg had adverse event rates comparable to monthly palivizumab in season 1 (primary outcome). RSV lower respiratory infection: 3.2% vs 3.4%. A 210 mg dose in season 2 (n=276) was well tolerated.
RCTn = 997
Zar et al. Clesrovimab in Infants at Increased Risk For Severe Disease During 2 RSV Seasons: A Randomized Clinical Trial